A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults

European Journal of Endocrinology

Volumn 147, Issue 1, 2002, Pages 49-57

  Ekman, B ^a   Lindstrom T ^a   Nystrom F ^a   Olsson, A G ^a   Toss, G ^a   Arnqvist, H J ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CORTISONE; DESMOPRESSIN; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRONE; ETHINYLESTRADIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; INSULIN; LEVONORGESTREL; LEVOTHYROXINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DOSE RESPONSE; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONE DEFICIENCY; HORMONE SENSITIVITY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOPITUITARISM; INSULIN SENSITIVITY; MALE; MUSCULOSKELETAL DISEASE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REFERENCE VALUE; SEX DIFFERENCE; SEXUAL DYSFUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036319580     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1470049     Document Type: Article

References (39)

1. Premature mortality due to cardiovascular disease in hypopituitarism
2. Mortality and cancer incidence in acromegaly: A retrospective cohort study
3. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy
4. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
5. Beneficial effects of growth hormone treatment in GH-deficient adults
6. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults
7. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors
8. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers
9. Population-based reference values for IGF-I and IGF-binding protein-1: Relations with metabolic and anthropometric variables
10. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects
11. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults
12. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults
13. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans
14. 2 determination by a combined ultracentrifugation and precipitation procedure
15. Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia
16. A low starting dose of genotropin in growth hormone-deficient adults
17. The growth hormone deficiency syndrome in adults
18. Enhancement of the peripheral sensitivity to growth hormone in adults with GH deficiency
19. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women
20. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender
21. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women
22. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults
23. A switch from oral (2 mg/day) to transdermal (50 microg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency
24. Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency
25. Secretory patterns of growth hormone according to sex and age
26. Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: A dose-finding study
27. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: Importance of endogenous estradiol concentrations
28. Growth hormone-deficient adults are insulin-resistant
29. Insulin sensitivity in growth hormone (GH)-deficient adults and effect of GH replacement therapy
30. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body GH-deficient adults
31. A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance
32. Studies of hyperlipidemia in the HGH-deficient state
33. Cardiovascular risk factors in adult patients with growth hormone deficiency
34. Serum lipid levels in growth hormone-deficient men
35. Body composition in growth hormone-deficient adults
36. Banting lecture 1988. Role of insulin resistance in human disease
37. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations
38. An open 36-month study of lipid changes with growth hormone in adults: Lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency